Jiangsu Hengrui Pharmaceuticals Co., Ltd. filed a Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of 7,420,091 shares of common stock in Braveheart Bio, Inc. (NASDAQ:BRVE), representing 8.2% of the company's outstanding shares as of September 30, 2026.

Key Highlights

  • Beneficial ownership reported: Jiangsu Hengrui Pharmaceuticals Co., Ltd. disclosed beneficial ownership of 7,420,091 shares of Braveheart Bio common stock.
  • Ownership percentage: The 7,420,091 shares represent 8.2% of Braveheart Bio's outstanding common stock, according to the filing.
  • Share count basis: The 8.2% figure is calculated against 90,038,969 shares of common stock outstanding, as reported by Braveheart Bio in its quarterly report filed September 8, 2026.
  • Sole voting and dispositive power: Jiangsu Hengrui holds sole power to vote and sole power to dispose of all 7,420,091 shares, with no shared voting or dispositive power reported.
  • Triggering event date: The event requiring this filing occurred on September 30, 2026.
  • Filer classification: Jiangsu Hengrui Pharmaceuticals Co., Ltd. is organized in the People's Republic of China and is classified as a corporation in the filing.

Hengrui's Reported Stake in Braveheart Bio, a San Francisco-Based Biopharmaceutical Company

Jiangsu Hengrui Pharmaceuticals Co., Ltd., a corporation organized in the People's Republic of China with its principal office at No. 7 Kunlunshan Road, Economic and Technological Development Zone, Lianyungang, Jiangsu, filed a Schedule 13G disclosing a significant passive ownership position in Braveheart Bio, Inc. Braveheart Bio is a biopharmaceutical company headquartered at One Letterman Drive, Building A, Suite A4-300, San Francisco, CA 94129, and its common stock carries a par value of $0.0001 per share with CUSIP number 10567X101.

According to the filing, Jiangsu Hengrui holds 7,420,091 shares of Braveheart Bio common stock, all attributed to Jiangsu Hengrui directly, with no shares held through subsidiaries or as part of a group. The percentage of class, 8.2%, was calculated by the filer using the 90,038,969 total shares outstanding figure disclosed in Braveheart Bio's own quarterly report filed with the SEC on September 8, 2026. The filing states that Jiangsu Hengrui holds sole voting power and sole dispositive power over all 7,420,091 shares, while shared voting power and shared dispositive power are each reported as zero.

The statement was signed on November 9, 2026, by Lau Kin Chun, Chief Financial Officer of Jiangsu Hengrui Pharmaceuticals Co., Ltd. The filing certifies that "the information set forth in this statement is true, complete and correct." Items covering ownership on behalf of another person, group membership, and subsidiary acquisition are each marked "Not Applicable" in the disclosure.

What Was Disclosed

Jiangsu Hengrui Pharmaceuticals Co., Ltd. disclosed beneficial ownership of 7,420,091 shares, or 8.2%, of Braveheart Bio, Inc. common stock via a Schedule 13G filed November 9, 2026, with a triggering event date of September 30, 2026.